NeoClinical Launches Neo PayPerPatient Solution for Asia-Pac
NeoClinical™, the leading digital clinical trial recruitment agency for Australia, New Zealand and Asian markets todayofficially launched its latest recruitment product, Neo PayPerPatient click here.
Neo PayPerPatient has emerged from 6 months of beta testing, including regulatory compliance, and integration of some of the latest online consumer engagement software and tools. Neo PayPerPatient has already built powerful databases of people wanting more information about the latest clinical trials for conditions including gout, arthritis, Alzheimer’s, menopause, diabetes, prostate cancer and asthma.
Neo PayPerPatient is a risk share pay-as-you-go solution for new studies or current studies that are underperforming and need a boost to recruitment. Sponsors only pay a nominal fee for partially screened patients then a moderate fee for those that proceed to full enrolment. NeoClinical™ manages all the rest. NeoClinical™‘s advertising and PR expertise as well as the team’s considerable online and social media experience to deliver results for clients. NeoClinical™ study recruitment campaigns feature innovative and EC compliant advertising, public relations and online content marketing campaigns.
NeoClinical™ typically achieves referral conversion rates of 40-60% and recently achieved a 63% conversion rate for a New Zealand Study.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
